This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dong, J. Articles by Aaronson, S. A. Search for Related Content PubMed PubMed Citation Articles by Dong, J. Articles by Aaronson, S. A.

BRAF Oncogenic Mutations Correlate with Progression rather than Initiation of Human Melanoma¹

Department of Pathology [J. D., R. G. P.], Ruttenberg Cancer Center [J. D., R. Q., S. Y., O. B., Z. R., S. A. A.], and Department of Dermatology [R. G. P.], Mount Sinai School of Medicine, New York, New York 10029

BRAF oncogenic mutations have been identified in significant numbers of melanocytic lesions. To correlate BRAF mutation and melanoma progression, we screened BRAF mutations in 65 melanocytic lesions, including nevi, radial growth phase (RGP), vertical growth phase (VGP) melanomas, and melanoma metastases, as well as 25 melanoma cell lines. PCR and direct sequencing were used to analyze DNA samples extracted from laser capture microdissected tissues. A similar high frequency (62–72%) of BRAF oncogenic mutations was identified in melanocytic nevi, VGP, metastatic melanomas, and melanoma cell lines [H. Davies et al., Nature (Lond.), 417: 949–954, 2002; P. M. Pollock et al., Nat. Genet., 33: 19–20, 2002; and M. S. Brose et al., Cancer Res., 62: 6997–7000, 2002]. In striking contrast, we found BRAF lesions in only 10% of the earliest stage or RGP melanomas. These findings imply that BRAF mutations cannot be involved in the initiation of the great majority of melanomas but instead reflect a progression event with important prognostic implications in the transition from the great majority of RGP melanomas to VGP and/or metastatic melanoma.

This article has been cited by other articles:

				M. Cheung, A. Sharma, S. V. Madhunapantula, and G. P. Robertson Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development Cancer Res., May 1, 2008; 68(9): 3429 - 3439. [Abstract] [Full Text] [PDF]

				R. M. Klein, L. S. Spofford, E. V. Abel, A. Ortiz, and A. E. Aplin B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization Mol. Biol. Cell, February 1, 2008; 19(2): 498 - 508. [Abstract] [Full Text] [PDF]

				V. N. Ivanov, H. Zhou, and T. K. Hei Sequential Treatment by Ionizing Radiation and Sodium Arsenite Dramatically Accelerates TRAIL-Mediated Apoptosis of Human Melanoma Cells Cancer Res., June 1, 2007; 67(11): 5397 - 5407. [Abstract] [Full Text] [PDF]

				M. Yancovitz, J. Yoon, M. Mikhail, W. Gai, R. L. Shapiro, R. S. Berman, A. C. Pavlick, P. B. Chapman, I. Osman, and D. Polsky Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma J. Mol. Diagn., April 1, 2007; 9(2): 178 - 183. [Abstract] [Full Text] [PDF]

				M. Shinozaki, S. J. O'Day, M. Kitago, F. Amersi, C. Kuo, J. Kim, H.-J. Wang, and D. S.B. Hoon Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy Clin. Cancer Res., April 1, 2007; 13(7): 2068 - 2074. [Abstract] [Full Text] [PDF]

				C. S. Mitsiades, J. Negri, C. McMullan, D. W. McMillin, E. Sozopoulos, G. Fanourakis, G. Voutsinas, S. Tseleni-Balafouta, V. Poulaki, D. Batt, et al. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications Mol. Cancer Ther., March 1, 2007; 6(3): 1070 - 1078. [Abstract] [Full Text] [PDF]

				M. R. James, T. Dumeni, M. S. Stark, D. L. Duffy, G. W. Montgomery, N. G. Martin, and N. K. Hayward Rapid Screening of 4000 Individuals for Germ-line Variations in the BRAF Gene Clin. Chem., September 1, 2006; 52(9): 1675 - 1678. [Abstract] [Full Text] [PDF]

				K. S.M. Smalley, N. K. Haass, P. A. Brafford, M. Lioni, K. T. Flaherty, and M. Herlyn Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol. Cancer Ther., May 1, 2006; 5(5): 1136 - 1144. [Abstract] [Full Text] [PDF]

				E. Hacker, H. K. Muller, N. Irwin, B. Gabrielli, D. Lincoln, S. Pavey, M. B. Powell, M. Malumbres, M. Barbacid, N. Hayward, et al. Spontaneous and UV Radiation-Induced Multiple Metastatic Melanomas in Cdk4R24C/R24C/TPras Mice. Cancer Res., March 15, 2006; 66(6): 2946 - 2952. [Abstract] [Full Text] [PDF]

				R. Somasundaram, R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, et al. Human Leukocyte Antigen-A2-Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients. Cancer Res., March 15, 2006; 66(6): 3287 - 3293. [Abstract] [Full Text] [PDF]

				K. S.M. SMALLEY and M. HERLYN Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 16 - 25. [Abstract] [Full Text] [PDF]

				M. Konopleva, Y. Shi, L. S. Steelman, J. G. Shelton, M. Munsell, F. Marini, T. McQueen, R. Contractor, J. A. McCubrey, and M. Andreeff Development of a Conditional In vivo Model to Evaluate the Efficacy of Small Molecule Inhibitors for the Treatment of Raf-Transformed Hematopoietic Cells Cancer Res., November 1, 2005; 65(21): 9962 - 9970. [Abstract] [Full Text] [PDF]

				C W Wong, Y S Fan, T L Chan, A S W Chan, L C Ho, T K F Ma, the Cancer Genome Project, S T Yuen, and S Y Leung BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs J. Clin. Pathol., June 1, 2005; 58(6): 640 - 644. [Abstract] [Full Text] [PDF]

				N. H. Tran, X. Wu, and J. A. Frost B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms J. Biol. Chem., April 22, 2005; 280(16): 16244 - 16253. [Abstract] [Full Text] [PDF]

				E. Grafstrom, S. Egyhazi, U. Ringborg, J. Hansson, and A. Platz Biallelic Deletions in INK4 in Cutaneous Melanoma Are Common and Associated with Decreased Survival Clin. Cancer Res., April 15, 2005; 11(8): 2991 - 2997. [Abstract] [Full Text] [PDF]

				J. J. Manfredi, J. Dong, W.-j. Liu, L. Resnick-Silverman, R. Qiao, P. Chahinian, M. Saric, A. R. Gibbs, J. I. Phillips, J. Murray, et al. Evidence against a Role for SV40 in Human Mesothelioma Cancer Res., April 1, 2005; 65(7): 2602 - 2609. [Abstract] [Full Text] [PDF]

				R. Steinmetz, H. A. Wagoner, P. Zeng, J. R. Hammond, T. S. Hannon, J. L. Meyers, and O. H. Pescovitz Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell Proliferation Mol. Endocrinol., October 1, 2004; 18(10): 2570 - 2582. [Abstract] [Full Text] [PDF]

				T. Nakatsura, T. Kageshita, S. Ito, K. Wakamatsu, M. Monji, Y. Ikuta, S. Senju, T. Ono, and Y. Nishimura Identification of Glypican-3 as a Novel Tumor Marker for Melanoma Clin. Cancer Res., October 1, 2004; 10(19): 6612 - 6621. [Abstract] [Full Text] [PDF]

				D. Tsavachidou, M. L. Coleman, G. Athanasiadis, S. Li, J. D. Licht, M. F. Olson, and B. L. Weber SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant Cancer Res., August 15, 2004; 64(16): 5556 - 5559. [Abstract] [Full Text] [PDF]

				J. T. Huntington, J. M. Shields, C. J. Der, C. A. Wyatt, U. Benbow, C. L. Slingluff Jr., and C. E. Brinckerhoff Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells: ROLE OF BRAF MUTATION AND FIBROBLAST GROWTH FACTOR SIGNALING J. Biol. Chem., August 6, 2004; 279(32): 33168 - 33176. [Abstract] [Full Text] [PDF]

				M. M. Schuierer, F. Bataille, S. Hagan, W. Kolch, and A.-K. Bosserhoff Reduction in Raf Kinase Inhibitor Protein Expression Is Associated with Increased Ras-Extracellular Signal-Regulated Kinase Signaling in Melanoma Cell Lines Cancer Res., August 1, 2004; 64(15): 5186 - 5192. [Abstract] [Full Text] [PDF]

				Y. Cohen, E. Rosenbaum, S. Begum, D. Goldenberg, C. Esche, O. Lavie, D. Sidransky, and W. H. Westra Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites Clin. Cancer Res., May 15, 2004; 10(10): 3444 - 3447. [Abstract] [Full Text] [PDF]

				C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C. J. Springer, and R. Marais V599EB-RAF is an Oncogene in Melanocytes Cancer Res., April 1, 2004; 64(7): 2338 - 2342. [Abstract] [Full Text] [PDF]

				Y. Mori, J. Yin, F. Sato, A. Sterian, L. A. Simms, F. M. Selaru, K. Schulmann, Y. Xu, A. Olaru, S. Wang, et al. Identification of Genes Uniquely Involved in Frequent Microsatellite Instability Colon Carcinogenesis by Expression Profiling Combined with Epigenetic Scanning Cancer Res., April 1, 2004; 64(7): 2434 - 2438. [Abstract] [Full Text] [PDF]

				R H Edwards, M R Ward, H Wu, C A Medina, M S Brose, P Volpe, S Nussen-Lee, H M Haupt, A M Martin, M Herlyn, et al. Absence of BRAF mutations in UV-protected mucosal melanomas J. Med. Genet., April 1, 2004; 41(4): 270 - 272. [Abstract] [Full Text] [PDF]

				M. S. Sharkey, G. Lizee, M. I. Gonzales, S. Patel, and S. L. Topalian CD4+ T-Cell Recognition of Mutated B-RAF in Melanoma Patients Harboring the V599E Mutation Cancer Res., March 1, 2004; 64(5): 1595 - 1599. [Abstract] [Full Text] [PDF]

				M. Shinozaki, A. Fujimoto, D. L. Morton, and D. S. B. Hoon Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas Clin. Cancer Res., March 1, 2004; 10(5): 1753 - 1757. [Abstract] [Full Text] [PDF]

				J. Alsina, D. H. Gorsk, F. J. Germino, W. Shih, S.-E. Lu, Z.-G. Zhang, J.-M. Yang, W. N. Hait, and J. S. Goydos Detection of Mutations in the Mitogen-Activated Protein Kinase Pathway in Human Melanoma Clin. Cancer Res., December 15, 2003; 9(17): 6419 - 6425. [Abstract] [Full Text] [PDF]

				K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression Clin. Cancer Res., December 15, 2003; 9(17): 6483 - 6488. [Abstract] [Full Text] [PDF]